CALL US AT (515) 598-7654

​​Dr. Vellareddy Anantharam has over 20 years of research experience in molecular neurobiology, pharmacology and toxicology in both the academic and corporate sectors. He has more than 75 published research papers to his credit. As a pharmacology faculty at the Univ. of Massachusetts Medical Center (1990-95) his major focus here was to study the effect of ethanol and local anesthetics on Neuronal ligand-gated and ion-gated channels. Subsequently, he joined the research team headed by Dr. Alan J Tobin, Director of Brain Research Institute, UCLA (1995-97). His team focused on engineering immortalized neuronal cell lines to express GAD65 and produce GABA for transplantation experiments in animal models of Epilepsy, Parkinson’s and Huntington disease.

In his position as a senior scientist (1997-99), Dr. Anantharam was instrumental in developing high-throughput pharmacological screening and cellular response measuring instruments at Axiom Biotechnologies Inc. (merged with Sequenom Inc.). In 1999 he won the employee of the year award. Since, 2000, he is an affiliate Associate Professor in the Department of Biomedical Sciences in the College of Veterinary Medicine, Iowa State University. At ISU, Dr. Anantharam’s research focuses on areas of neurodegenerative diseases and neurotoxicology. In 2006, he co-founded PK Bio. In 2008, he received NIH SBIR phase I funding for development of Novel Therapeutic Agents for Parkinson’s’ disease. In 2008, he also received the Iowa Technological Commercialization Fellowship Award. In 2009 he also received funding from Grow Iowa Value Fund and Institute for Physical Research and Technology from the State of Iowa for syntheses and screening of novel drugs for PD. 

Dr. Anantharam began his post doctoral training at Johns Hopkins Medical School in the laboratory of Professor Pete C Maloney. He received Doctoral degrees in Molecular Biophysics from Indian Institute of Science, Bangalore.

vellareddy anantharam

Chief Scientific Officer and Chief Operating Officer

Dr. Anumantha G Kanthasamy is the President and CEO. He has over 20 years of research experience in neuroscience, pharmacology and toxicology. Dr. Kanthasamy is also Distinguished Professor and the Eugene and Linda Lloyd Endowed Chair of Neurotoxicology in the Department of Biomedical Sciences at the College of Veterinary Medicine, Iowa State University. He is also the chair of the Interdepartmental Toxicology Graduate Program and is the founding director of the Iowa Center for Advanced Neurotoxicology (ICAN). Prior to joining ISU, he was a faculty member in the Department of Neurology, University of California, Irvine, CA, and was a researcher at Purdue University, West Lafayette, IN. He has worked as a scientist in various pharmaceutical industries.

Currently, Dr. Kanthasamy’s research is focused primarily in the areas of neuropharmacology and neurotoxicology, His major study emphasis is on cellular and molecular mechanisms associated with oxidative cell death signaling pathways as they relate to the pathogenesis of Parkinson’s disease and other associated neurological disorders. In support of the neuronpharmacological and toxicological research being conducted at ISU, Dr. Kanthasamy has secured several million dollars in funding from the National Institute of Health and other funding agencies. Also, he has received contracts from many pharmaceutical/biotechnology companies including Merck KGaA and BoehringerIngelheimPharmaGmbH&Co KG., Biotherapeutix, and Hematech. Dr. Kanthasamy is a prolific author, with more than 100 published research papers and abstracts, and is a frequent invited lecturer at numerous conferences worldwide. At ISU, Dr. Kanthasamy teaches toxicology and pharmacology courses to graduate students and veterinary medical students. He regularly serves on a variety of prestigious panels including NIH study section review panels and other grant review committees.

Dr. Kanthasamy’s career is distinguished by a long list of awards, honors and recognitions he has received over the years. He also maintains memberships in many preeminent professional organizations including the Society of Toxicology, Society for Neuroscience, American Society of Pharmacology Experimental Therapeutics, and International Neurochemistry Society.

As a development-stage company PK Biosciences Corporation value its success on partnership, collaboration and equity investment from pharmaceutical industries and venture capital investment.
We are continually looking for business partners/collaborators/ investors who can see the true long-term value of investment in this company.

Anumantha G. KanTHasamy

President & Chief Executive Officer

PK Bio is working towards developing innovative oral medicines targeting to improve the health of patients with neurodegenerative diseases. PK Bios’ innovative medicines are targeted against selective cell death signaling molecules, which are involved in the cell survival and apoptotic cell death  observed in many neurodegenerative disorders including Amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s  and Huntington diseases. PK Bios’ small molecule therapeutics candidates provide a novel neuroprotective and anti-neuroinflammatory approach designed to maximize clinical outcome and limit off-target effects.

PK Bio is a private held company with corporate values.  We strive for excellence, high level of productivity, conduct with integrity & high ethical standards.  We respect the functional expertise and role of our colleagues. We value diversity in culture, experiences and work style.

​PK Biosciences

Dr. Ravi Kiron based in San Jose, CA, is an experienced pharma/biotech executive with decades of experience in discovery R&D through late-stage clinical development, intellectual property and regulatory, technology & business development, Strategy and product commercialization, negotiating and executing partnerships by leveraging his extensive global business development networks in CVMD, Oncology, CNS, Wound Healing, Microbiome, Orphan/Rare Disease and Diagnostics.

He was a tenure-track faculty member at Cornell University Medical College and adjunct faculty at University of Rhode Island. Dr. Kiron served in various Operational & Senior Management roles at Pfizer Inc., and Johnson & Johnson (ALZA), across various Therapeutic Areas - Cardiovascular R&D, Oncology clinical development (Tarceva), Strategic business development and M&A (WLA, PHA & other biotechs).  Dr. Kiron has consulted for several dozen global life sciences companies, founded and led multiple new ventures, served as an EIR at SRI Ventures, ShangPharma Innovation and advises company and non-profit boards.

Dr. Kiron earned a BS in Chemistry and an MS in Microbiology from the University of Mumbai, a PhD in Biochemistry from the Indian Institute of Science, India and an MBA from Rensselaer Polytechnic Institute, New York, USA.


Chief Business Officer

investor Relations

Learn More

About Us

Company overview

We are aN INNOVATIVE biotechnology company